-
EVIDENCE READINESS FOR HEOR-ORIENTED VALUE ASSESSMENT IN EUROPEAN VBHC INITIATIVES: A CROSS-CASE STUDY OF 40 EAVH-MAPPED CASES
Aug 11, 2026, 17:16 PM -
ESTIMATING LIFE-YEAR GAINS OF TUMOR TREATING FIELDS AFTER FIRST PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA
Aug 11, 2026, 17:16 PM -
COMPARISON OF THE MEASUREMENT PROPERTIES OF EQ-5D-5L AND SF-6DV2 IN KOREAN PATIENTS WITH LUMBAR SPINAL STENOSIS
Aug 11, 2026, 17:16 PM -
HEALTH ECONOMIC ASSESSMENT OF ENDOSCOPIC SLEEVE GASTROPLASTY VERSUS LAPAROSCOPIC SLEEVE GASTRECTOMY FOR PRIVATE SAUDI HEALTH INSURERS
Aug 11, 2026, 17:16 PM -
AMPLIFIED GLOBAL WELFARE EFFECTS OF NICE'S PROPOSED 25% COST-EFFECTIVENESS THRESHOLD UPLIFT THROUGH INTERNATIONAL REFERENCE PRICING
Aug 11, 2026, 17:16 PM -
ACCELERATING RWE TREATMENT PATTERN SYNTHESIS THROUGH AI-ASSISTED LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF PROVIDING FULL HOME ENTERAL NUTRITION THROUGH THE PUBLIC HEALTH SYSTEM IN SãO PAULO, BRAZIL
Aug 11, 2026, 17:16 PM -
THE ECONOMIC AND HUMANISTIC BURDEN OF PULMONARY ARTERIAL HYPERTENSION IN OMAN
Aug 11, 2026, 17:16 PM -
CUMULATIVE ECONOMIC AND SOCIETAL BURDEN OF GRADE 2 MIDH GLIOMA ON PATIENTS AND CAREGIVERS, STRATIFIED BY RADIOTHERAPY/CHEMOTHERAPY EXPOSURE
Aug 11, 2026, 17:16 PM -
REAL-WORLD OBESITY AND GLP-1RA TOLERABILITY: INCIDENCE AND PROGNOSTIC RISK FACTORS OF SERIOUS GI ADVERSE EVENTS USING FEDERATED LEARNING
Aug 11, 2026, 17:16 PM -
NICE COMMITTEE DECISIONS AND REASONING AROUND ACCEPTABLE ICERS IN THE YEAR LEADING UP TO THE APRIL 2026 THRESHOLD RANGE CHANGE
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF ION AS A BIOPSY TOOL FOR PATIENTS CURRENTLY INELIGIBLE FOR BIOPSY IN THE LUNG CANCER DIAGNOSTIC PATHWAY
Aug 11, 2026, 17:16 PM -
HOW DO HTA SYSTEMS AND PAYERS RECOGNISE THERAPEUTIC COMPARABILITY? A CROSS-MARKET ASSESSMENT OF COST-ADVANTAGE REIMBURSEMENT PATHWAYS
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND STRUCTURAL BENCHMARKING OF THE ASSURE-SSP MODEL: ASUNDEXIAN REFERENCE ECONOMIC MODEL IN SECONDARY STROKE PREVENTION
Aug 11, 2026, 17:16 PM -
DUAL BRAND STRATEGY IN GERMAN DRUG PRICING: LIMITED OPPORTUNITY BASED ON AMNOG FRAMEWORK WITH EXCEPTIONS?
Aug 11, 2026, 17:16 PM -
PATIENT PREFERENCES FOR BENEFIT-RISK TRADE-OFFS AND EVIDENCE UNCERTAINTY OF ANTI-AMYLOID THERAPIES IN EARLY ALZHEIMER'S DISEASE: A DISCRETE CHOICE EXPERIMENT
Aug 11, 2026, 17:16 PM -
GLUCAGON-LIKE PEPTIDE-1-BASED ANTI-OBESITY MEDICATIONS REDUCE INCIDENT OBSTRUCTIVE SLEEP APNEA IN OLDER ADULTS: REAL-WORLD EVIDENCE
Aug 11, 2026, 17:16 PM -
GLOBAL REGULATORY CHALLENGES AND PATIENT SAFETY CONCERNS IN NEW-AGE TECHNOLOGY-BASED MEDICAL DEVICES A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF MALE SLING AND ARTIFICIAL URINARY SPHINCTER FOR URETHRAL SPHINCTER DEFICIENCY IN THAILAND
Aug 11, 2026, 17:16 PM -
MOST FAVOURED NATION, LEAST FAVOURED MARKETS? EU5 PAYER PERSPECTIVES ON US PRICING REFORMS
Aug 11, 2026, 17:16 PM
